Compare Crispr Therapeutics AG (CRSP) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs United Airlines Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $51.39 (market cap $4.97B), while United Airlines Holdings Inc trades at $118.41 (market cap $39.06B). The key difference: United Airlines Holdings Inc is far larger — about 7.9× Crispr Therapeutics AG's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | UAL | |
|---|---|---|
Market Cap | $4.97B | $39.06B |
Sector | Health | Industrials |
52-Week High | $76.78 | $136.11 |
52-Week Low | $44.34 | $84.57 |
Enterprise Value | $3.32B | $55.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
United Airlines (UAL) trades at $121.16, down 3.84% amid sector volatility, with strong fundamentals including a P/E of 10.84 and net income margin of 6.06%. Recent earnings beats and a bullish analyst consensus (66% buy ratings) support a $160.88 price target. Cash flow trends show operational strength despite net outflows, while technical indicators signal near-term support at $120.
Outlook remains positive with projected revenue growth to $60.5B in 2026, though risks include fuel cost spikes and competitive pressures. The stock offers value with low valuation multiples and consistent earnings outperformance, positioning it for recovery if macroeconomic headwinds ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
